This is a preview of subscription content, log in via an institution to check access.
References
The EuroQol Group (1990) EuroQol–a new facility for the measurement of health-related quality of life. Heal pol 16:199–208
Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR, Fampridine MSFI (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373:732–738
Hourez R, Servais L, Orduz D, Gall D, Millard I, de Kerchove d’Exaerde A, Cheron G, Orr HT, Pandolfo M, Schiffmann SN (2011) Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J neurosci the off J Soc Neurosci 31:11795–11807
Jacobi H, Rakowicz M, Rola R, Fancellu R, Mariotti C, Charles P, Durr A, Kuper M, Timmann D, Linnemann C, Schols L, Kaut O, Schaub C, Filla A, Baliko L, Melegh B, Kang JS, Giunti P, van de Warrenburg BP, Fimmers R, Klockgether T (2013) Inventory of non-ataxia signs (INAS): validation of a new clinical assessment instrument. Cerebellum 12:418–428
Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowicz M, Ribai P, Rola R, Schols L, Szymanski S, van de Warrenburg BP, Durr A, Klockgether T, Fancellu R (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717–1720
Schmitz-Hubsch T, Giunti P, Stephenson DA, Globas C, Baliko L, Sacca F, Mariotti C, Rakowicz M, Szymanski S, Infante J, van de Warrenburg BP, Timmann D, Fancellu R, Rola R, Depondt C, Schols L, Zdzienicka E, Kang JS, Dohlinger S, Kremer B, Melegh B, Filla A, Klockgether T (2008) SCA functional index: a useful compound performance measure for spinocerebellar ataxia. Neurology 71:486–492
Schniepp R, Wuehr M, Ackl N, Danek A, Brandt T, Strupp M, Jahn K (2011) 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation. J Neurol 258:1708–1711
Schniepp R, Wuehr M, Neuhaeusser M, Benecke AK, Adrion C, Brandt T, Strupp M, Jahn K (2012) 4-aminopyridine and cerebellar gait: a retrospective case series. J Neurol 259:2491–2493
Strupp M, Kalla R, Claassen J, Adrion C, Mansmann U, Klopstock T, Freilinger T, Neugebauer H, Spiegel R, Dichgans M, Lehmann-Horn F, Jurkat-Rott K, Brandt T, Jen JC, Jahn K (2011) A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 77:269–275
Zesiewicz TA, Greenstein PE, Sullivan KL, Wecker L, Miller A, Jahan I, Chen R, Perlman SL (2012) A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 78:545–550
Acknowledgments
We would like to thank all the people that participated in this study.
Conflicts of interest
The authors declare that they have no conflict of interest.
Ethical standard
This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Giordano, I., Bogdanow, M., Jacobi, H. et al. Experience in a short-term trial with 4-Aminopyridine in cerebellar ataxia. J Neurol 260, 2175–2176 (2013). https://doi.org/10.1007/s00415-013-7029-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-013-7029-5